Prestige Consumer Healthcare Inc (NYSE:PBH) Q2 2025 Results Conference Call November 7, 2024 8:30 AM ET

Company Participants

Phil Terpolilli - Vice President, Investor Relations
Ron Lombardi - Chairman, President & Chief Executive Officer
Chris Sacco - Chief Financial Officer

Conference Call Participants

Rupesh Parikh - Oppenheimer
Susan Anderson - Canaccord
Anthony Lebiedzinski - Sidoti & Co.

Operator

Good day, ladies and gentlemen, and welcome to Prestige Consumer Healthcare's Second Quarter 2025 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to introduce your host for today's conference call, Phil Terpolilli, Vice President, Investor Relations. Please go ahead.

Phil Terpolilli

Thanks, operator, and thank you to everyone who has joined today. On the call with me are Ron Lombardi, our Chairman, President and CEO; and Christine Sacco, our CFO.

On today's call, we'll review the second quarter fiscal 2025 results, discuss our full year outlook and then take questions from analysts. A slide presentation that accompanies today's call can be accessed by visiting prestigeconsumerhealthcare.com, clicking on the Investors link and then on today's webcast and presentation.

Remember, some of the information contained in the presentation today includes non-GAAP financial measures. Reconciliations to the nearest GAAP financial measure are included in our earnings release and slide presentation.

On today's call, management will make forward-looking statements around risks and uncertainties, which are detailed in a complete safe harbor disclosure on Page 2 of the slide presentation that accompanies the call. These are important to review and contemplate. Business environment uncertainty remains heightened due to supply chain constraints and inflation, which have numerous potential impacts. This means results could change at any time, and the forecasted impact of risk considerations is the best estimate based on the information available as of today. Additional information concerning risk factors and cautionary statements are available in our most recent SEC filings and our most recent company 10-K.

I'll now hand it over to our CEO, Ron Lombardi. Ron?

Ron Lombardi

Thanks, Phil. Let's begin on Slide 5.

Our Q2 results exceeded the expectations we communicated back in August and improved on Q1. Sales of $284 million declined slightly versus the prior year, largely due to Clear Eyes supply chain limitations and Q1 timing. I'll provide an update on Clear Eyes in our wrap-up. Thanks to our diverse portfolio, we offset most of this decline in other business areas, led by strong and broad-based growth in our International segment and its Hydralyte brand, as well as our Canadian portfolio, which I'll touch on shortly. Resulting earnings and cash flow were stable in Q2 thanks to our business strategy and disciplined capital deployment.